As the cost of air pollution rises, a company that had spent years fighting to curb the spread of airborne pollutants has come up with a solution that could help solve one of the world’s biggest health problems: pollution.
The solution: a single-dose nasal spray that helps people who breathe in harmful pollutants avoid coughing and wheezing.
The U.S. Centers for Disease Control and Prevention recently announced it had found evidence that the spray was effective in combating the spread and deaths of coronavirus, the virus that causes most cases of pneumonia, bronchitis, and emphysema.
But it’s not just about avoiding coughs and wheeze.
The spray also helps reduce other lung infections, which are the leading cause of death in the United States, the agency said.
The American Lung Association, which represents air-quality and respiratory-health experts, has called Cornell’s solution “groundbreaking.”
In a statement, the association called it a “game changer” that will “lead to a safer air and more efficient breathing environment for Americans, for our communities, and for our planet.”
Cornell has been working with the American Lung Assn.
for nearly a decade, the group said.
But the company had yet to show that its nasal spray helped prevent the spread or deaths of the coronaviruses.
“Cornell has developed a unique product that will dramatically reduce the impact of coronovirus, and it’s a game-changer for the air we breathe,” said Tim Hirsch, the American Heart Association’s chief scientific officer, in a statement.
“This groundbreaking research will benefit our air quality and protect our children and families from air pollution.”
In the United Kingdom, researchers found that the use of Cornell nasal spray actually reduced the incidence of respiratory-infections, such as coronaviral pneumonia, as much as 90 percent.
The product, called CQ-3, is available in pharmacies, as well as online.
The company’s nasal spray has a spray that’s made from a combination of organic cotton, vegetable oil, and water, which it uses to dry.
But its aerosol is made from carbon dioxide, a greenhouse gas that can also produce harmful particulates and ozone.
As the world continues to experience its deadliest year on record, coronavirosts have become increasingly common.
The World Health Organization said in January that there are now 2.2 million new coronavire cases worldwide, and nearly 5 million deaths.
The WHO also reported a sharp rise in the number of coronavalcovirus infections, up more than 20 percent from the same period last year.
More than half of those cases have been in Asia, where coronavisis has surged in recent years, especially in China, Vietnam, and other Asian countries.
The increase has also come from new infections in the developing world, including in Nigeria and South Africa, where there were more than 4 million new cases last year, and in India, where the country’s new coronavalvirus epidemic is the worst on record.
As more and more people become infected with the virus, coronavalovirus deaths are projected to increase, and experts warn that a growing number of new cases could turn into an epidemic.
In the U.K., a study published last week by the British Medical Journal estimated that a coronavioid outbreak could result in a total of 20,000 deaths by 2050.
That number would be about double the number that occurred in the same time frame last year and would surpass the number from the 1980s.
“We need to be able to get the population to get vaccinated,” said Dr. Nick Boulton, director of the University of Southampton’s coronaviolence unit.
“If you’re going to have a vaccine, you need to get it to the population.”
Boulston said that, as a first step, the country should begin vaccinating people who were previously not vaccinated, and also look to vaccinate children.
The study was based on data from more than 60 countries and included about 12,000 people.
The average age of the study’s participants was 55, which was the same age that they would have been if they hadn’t been vaccinated.
The researchers also looked at the impact that vaccines had on the spread, and the number and severity of the new cases.
In some cases, they found that there was no change in the amount of new coronoviral infections.
In others, however, there was a decline in the incidence.
In other cases, the decline was as much 10 percent or more.
And in some cases the decline may have been as much 40 percent.
In those cases, there were some differences in the effectiveness of the vaccine, with some people who had previously not been vaccinated developing a milder or stronger infection.
“The study clearly shows that there is a vaccine out there, and that we can get a lot of people vaccinated,” Bouloon said.
“And we can have a real impact on what